237 related articles for article (PubMed ID: 8642346)
1. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
Becker JC; Pancook JD; Gillies SD; Furukawa K; Reisfeld RA
J Exp Med; 1996 May; 183(5):2361-6. PubMed ID: 8642346
[TBL] [Abstract][Full Text] [Related]
2. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
[TBL] [Abstract][Full Text] [Related]
3. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
4. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.
Schrama D; Voigt H; Eggert AO; Xiang R; Reisfeld RA; Becker JC
Cancer Immunol Immunother; 2006 Jul; 55(7):861-6. PubMed ID: 16158274
[TBL] [Abstract][Full Text] [Related]
6. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
[TBL] [Abstract][Full Text] [Related]
7. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
8. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.
Becker JC; Varki N; Gillies SD; Furukawa K; Reisfeld RA
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7826-31. PubMed ID: 8755561
[TBL] [Abstract][Full Text] [Related]
9. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Proc Natl Acad Sci U S A; 1997 May; 94(11):5756-60. PubMed ID: 9159146
[TBL] [Abstract][Full Text] [Related]
10. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
11. Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies.
Law LW; Vieira WD; Hearing VJ; Gersten DM
Biochim Biophys Acta; 1994 Apr; 1226(1):105-9. PubMed ID: 7908833
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases.
Hirschowitz EA; Crystal RG
Am J Respir Cell Mol Biol; 1999 May; 20(5):935-41. PubMed ID: 10226063
[TBL] [Abstract][Full Text] [Related]
14. Immunocytokines: a new approach to immunotherapy of melanoma.
Reisfeld RA; Becker JC; Gillies SD
Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
[TBL] [Abstract][Full Text] [Related]
15. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
[TBL] [Abstract][Full Text] [Related]
16. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.
Ortaldo JR; Winkler-Pickett RT; Bere EW; Watanabe M; Murphy WJ; Wiltrout RH
J Immunol; 2005 Jul; 175(2):693-9. PubMed ID: 16002664
[TBL] [Abstract][Full Text] [Related]
17. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma.
Markovic SN; Murasko DM
Cancer Res; 1991 Feb; 51(4):1124-8. PubMed ID: 1705166
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
Lode HN; Xiang R; Dreier T; Varki NM; Gillies SD; Reisfeld RA
Blood; 1998 Mar; 91(5):1706-15. PubMed ID: 9473237
[TBL] [Abstract][Full Text] [Related]
19. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
20. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
